Seeking Alpha

Amgen (AMGN) announces positive results from a study of its cholesterol-fighting human...

Amgen (AMGN) announces positive results from a study of its cholesterol-fighting human monoclonal antibody AMG 145. The treatment reduces so-called bad cholesterol by up to 81%, according to data. Phase II results are due out later this year as Amgen tries to shoulder into the high-stakes Lipitor vs. generics battle.
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Tools
Find the right ETFs for your portfolio:
Seeking Alpha's new ETF Hub
ETF Investment Guide:
Table of Contents | One Page Summary
Read about different ETF Asset Classes:
ETF Selector

Next headline on your portfolio:

|